Building Your Multispecialty Care Team
At a Glance
Because mucous membrane pemphigoid can affect multiple mucosal sites, patients often need a dermatologist plus specialists for affected areas—such as the eyes, mouth, airway, or esophagus—to monitor for changes, share results, and keep treatment coordinated.
Because Mucous Membrane Pemphigoid (MMP) is a multi-site disease that can affect everything from your eyes to your airway, no single doctor can manage it alone. Successfully navigating this diagnosis requires a multidisciplinary team—a group of specialists who communicate regularly to ensure no part of your body is left unprotected [1][2].
While the healthcare system is responsible for your medical management, you play a vital role as an active partner in your care. By helping keep your records organized and asking the right questions, you help your team provide the best possible surveillance [1].
Your Essential Care Team
An effective MMP team is built around the specific areas where the disease is active or could potentially spread.
- Dermatologist: Often the “lead clinician” of the team, especially one who specializes in immunodermatology or autoimmune blistering diseases. They typically manage your systemic (whole-body) medications [3].
- Ophthalmologist: Crucial for baseline screening and ongoing monitoring, as ocular disease can be subtle in its early stages [4][1].
- Oral Medicine Specialist or Dentist: Focuses on the health of your gums and mouth. They help manage painful oral sores and provide strategies for maintaining hygiene when brushing is difficult [5][6].
- Otolaryngologist (ENT): Essential if you experience hoarseness, voice changes, or nosebleeds. They evaluate the throat and airway for signs of scarring based on symptoms or high-risk features [7][8].
- Gastroenterologist: Involved if you have difficulty swallowing, as they can screen for and treat esophageal strictures (narrowing) [3][9].
- Gynecologist or Urologist: Necessary if the disease affects the genital or urinary tracts, ensuring these sensitive areas are treated to prevent functional impairment [3][10].
Why Communication is Critical
MMP is unpredictable. A “negative” biopsy in one area (like the eye) does not always mean the disease isn’t present there, and new sites can become involved even while others are healing [1][11].
Cross-specialty communication ensures that:
- Silent progression is caught early through routine risk-based screenings of all mucosal sites [1].
- Treatment is unified, preventing situations where two different doctors prescribe conflicting medications [3].
- Biopsy results are shared, which can help confirm a diagnosis if a test at one site was inconclusive [11][12].
Vetting Your Specialists
Since MMP is rare (about 2 cases per million people), many excellent doctors may have limited experience with it. When meeting a new specialist, it is appropriate and empowered to ask:
- “How many patients with MMP have you treated?”
- “Are you familiar with the latest International Consensus Guidelines for MMP management?” [3]
- “Do you have a preferred lead clinician or clinic you coordinate with for rare autoimmune conditions?” [13]
If your case is high-risk or complex, your local team may suggest a consultation at a tertiary referral center—a university hospital or specialized clinic with a dedicated autoimmune blistering disease program [14][15].
Record-Sharing Checklist: Preparing for Your Visits
To make the most of your appointments and help your specialists work together, bring a physical or digital “MMP Binder” containing:
- [ ] Pathology Reports: The full text of your biopsy results, including the Direct Immunofluorescence (DIF) findings [3].
- [ ] Lab Results: Any blood tests for autoantibodies (like Anti-BP180 or Anti-Laminin-332) [16].
- [ ] Medication List: A current list of all prescriptions, including dosages and any side effects you’ve experienced.
- [ ] Disease Scores: Recent records of objective disease scores (like ODSS or Foster staging) from your previous appointments.
- [ ] Imaging: Reports from any endoscopies or CT scans related to your symptoms.
- [ ] Symptom Log: A brief history of when your symptoms started and which areas have been affected over time.
By arriving prepared and ensuring your specialists are in contact, you bridge the gaps in the healthcare system and ensure your care is as comprehensive as possible [2][1].
Common questions in this guide
Which specialists are usually involved in mucous membrane pemphigoid care?
Why does MMP care require communication between doctors?
What should I bring to an appointment with a new MMP specialist?
How can I find a doctor experienced in MMP?
Who should coordinate my MMP treatment plan?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Mucous membrane pemphigoid.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Who will be the 'lead' coordinator for my care to ensure all my specialists are following the same treatment plan?
- 2.How many patients with Mucous Membrane Pemphigoid (MMP) have you personally managed in the last year?
- 3.Do you have an established relationship with an ophthalmologist and ENT who specialize in autoimmune blistering diseases?
- 4.Will you be sharing my objective disease scores (like MMPDAI or ODSS) with my other doctors so we can all track my progress together?
- 5.How can I best reach you if I develop a new symptom in an area you don't typically treat (like my eyes or throat)?
References
References (16)
- 1
Mucous Membrane Pemphigoid with Ocular Involvement: The Clinical Phenotype and Its Relationship to Direct Immunofluorescence Findings.
Ong HS, Setterfield JF, Minassian DC, et al.
Ophthalmology 2018; (125(4)):496-504 doi:10.1016/j.ophtha.2017.10.004.
PMID: 29217149 - 2
S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid.
Hofmann SC, Günther C, Böckle BC, et al.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2022; (20(11)):1530-1550 doi:10.1111/ddg.14905.
PMID: 36354061 - 3
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.
Schmidt E, Rashid H, Marzano AV, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(10)):1926-1948 doi:10.1111/jdv.17395.
PMID: 34309078 - 4
Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment.
Georgoudis P, Sabatino F, Szentmary N, et al.
Ophthalmology and therapy 2019; (8(1)):5-17 doi:10.1007/s40123-019-0164-z.
PMID: 30694513 - 5
The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review.
Davis G, Hathway R, Shipley D, Staines K
British dental journal 2024; (236(4)):311-316 doi:10.1038/s41415-024-7074-8.
PMID: 38388610 - 6
Periodontitis in oral pemphigus and pemphigoid: A systematic review of published studies.
Jascholt I, Lai O, Zillikens D, Kasperkiewicz M
Journal of the American Academy of Dermatology 2017; (76(5)):975-978.e3 doi:10.1016/j.jaad.2016.10.028.
PMID: 28038889 - 7
High frequency of upper aerodigestive tract manifestations in mucous membrane pemphigoid.
Endo H, Rees TD, Niwa H, et al.
Oral diseases 2022; (28(6)):1555-1560 doi:10.1111/odi.13872.
PMID: 33835636 - 8
Mucous Membrane Pemphigoid Causing Central Airway Obstruction.
Jalil BA, Abdou YG, Rosen SA, Dammad T
Journal of bronchology & interventional pulmonology 2017; (24(4)):334-338 doi:10.1097/LBR.0000000000000374.
PMID: 28248822 - 9
Structured Diagnostic Approach and Risk Assessment in Mucous Membrane Pemphigoid with Oesophageal Involvement.
Benoit S, Scheurlen M, Goebeler M, Stoevesandt J
Acta dermato-venereologica 2018; (98(7)):660-666 doi:10.2340/00015555-2938.
PMID: 29648673 - 10
Ocular cicatricial pemphigoid (Review).
Branisteanu DC, Stoleriu G, Branisteanu DE, et al.
Experimental and therapeutic medicine 2020; (20(4)):3379-3382 doi:10.3892/etm.2020.8972.
PMID: 32905166 - 11
Assessment of Diagnostic Strategy for Mucous Membrane Pemphigoid.
Rashid H, Meijer JM, Diercks GFH, et al.
JAMA dermatology 2021; (157(7)):780-787 doi:10.1001/jamadermatol.2021.1036.
PMID: 33909024 - 12
Conjunctival Biopsy Site in Mucous Membrane Pemphigoid.
Coco G, Romano V, Menassa N, et al.
American journal of ophthalmology 2020; (216()):1-6 doi:10.1016/j.ajo.2020.01.033.
PMID: 32067959 - 13
Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review.
Lytvyn Y, Rahat S, Mufti A, et al.
Journal of the American Academy of Dermatology 2022; (87(1)):110-120 doi:10.1016/j.jaad.2020.12.056.
PMID: 33422625 - 14
On the Current Care Situation and Treatment of Ocular Mucous Membrane Pemphigoid in Germany.
Yaïci R, Roth M, Juergens L, et al.
Klinische Monatsblatter fur Augenheilkunde 2023; (240(9)):1077-1083 doi:10.1055/a-1720-1819.
PMID: 35609814 - 15
Mucous membrane pemphigoid-otorhinolaryngological manifestations: a retrospective cohort study.
Madgar O, Baniel A, Yarom N, et al.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2020; (277(3)):939-945 doi:10.1007/s00405-020-05812-3.
PMID: 31980882 - 16
State-of-the-art diagnosis of autoimmune blistering diseases.
van Beek N, Holtsche MM, Atefi I, et al.
Frontiers in immunology 2024; (15()):1363032 doi:10.3389/fimmu.2024.1363032.
PMID: 38903493
This page is for informational purposes only and does not constitute medical advice. It describes how people with MMP can coordinate specialists and records; your care team should tailor monitoring and treatment to your needs.